TAYSHA GENE THERAPIES INC's ticker is TSHA and the CUSIP is 877619106. A total of 65 filers reported holding TAYSHA GENE THERAPIES INC in Q3 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,562,254 | +378.1% | 810,840 | 0.0% | 0.00% | – |
| Q2 2023 | $535,965 | -17.1% | 810,840 | 0.0% | 0.00% | – |
| Q1 2023 | $646,726 | -64.7% | 810,840 | -0.0% | 0.00% | -100.0% |
| Q4 2022 | $1,833,016 | +17.1% | 811,069 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,565,000 | -48.1% | 811,069 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,017,000 | -64.4% | 811,069 | -37.6% | 0.00% | -66.7% |
| Q1 2022 | $8,480,000 | -44.4% | 1,300,668 | -0.6% | 0.00% | -40.0% |
| Q4 2021 | $15,244,000 | -37.5% | 1,308,533 | -0.1% | 0.01% | -44.4% |
| Q3 2021 | $24,396,000 | -11.9% | 1,310,210 | +0.3% | 0.01% | -18.2% |
| Q2 2021 | $27,684,000 | +21.9% | 1,305,846 | +16.7% | 0.01% | +22.2% |
| Q1 2021 | $22,719,000 | +7.1% | 1,119,169 | +40.0% | 0.01% | 0.0% |
| Q4 2020 | $21,220,000 | +18.3% | 799,529 | -0.1% | 0.01% | 0.0% |
| Q3 2020 | $17,932,000 | – | 800,520 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 1,391,190 | $29,493,000 | 22.62% |
| Octagon Capital Advisors LP | 320,440 | $6,793,000 | 1.41% |
| Artal Group S.A. | 1,040,882 | $22,067,000 | 0.45% |
| Alphabet Inc. | 640,882 | $13,587,000 | 0.28% |
| Nantahala Capital Management | 432,072 | $9,160,000 | 0.26% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 500,000 | $10,600,000 | 0.22% |
| TimesSquare Capital Management, LLC | 683,400 | $14,488,000 | 0.12% |
| Perceptive Advisors | 640,880 | $13,586,000 | 0.09% |
| Virtus ETF Advisers LLC | 8,697 | $184,000 | 0.08% |
| Granite Point Capital Management, L.P. | 50,000 | $1,060,000 | 0.04% |